• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

变革疫苗研发。

Transforming vaccine development.

作者信息

Black Steve, Bloom David E, Kaslow David C, Pecetta Simone, Rappuoli Rino

机构信息

Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.

Harvard T.H. Chan School of Public Health, Harvard University, Boston MA 02115, USA.

出版信息

Semin Immunol. 2020 Aug;50:101413. doi: 10.1016/j.smim.2020.101413. Epub 2020 Oct 28.

DOI:10.1016/j.smim.2020.101413
PMID:33127296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7591868/
Abstract

The urgency to develop vaccines against Covid-19 is putting pressure on the long and expensive development timelines that are normally required for development of lifesaving vaccines. There is a unique opportunity to take advantage of new technologies, the smart and flexible design of clinical trials, and evolving regulatory science to speed up vaccine development against Covid-19 and transform vaccine development altogether.

摘要

研发针对新冠病毒的疫苗的紧迫性,正给通常研发挽救生命的疫苗所需的漫长且昂贵的研发时间线带来压力。现在有一个独特的机会,可以利用新技术、临床试验的灵活巧妙设计以及不断发展的监管科学,来加速针对新冠病毒的疫苗研发,并彻底改变疫苗研发的整体状况。

相似文献

1
Transforming vaccine development.变革疫苗研发。
Semin Immunol. 2020 Aug;50:101413. doi: 10.1016/j.smim.2020.101413. Epub 2020 Oct 28.
2
The continued advance of vaccine adjuvants - 'we can work it out'.疫苗佐剂的不断进步——“我们可以解决它”。
Semin Immunol. 2020 Aug;50:101426. doi: 10.1016/j.smim.2020.101426. Epub 2020 Nov 27.
3
The immunology of SARS-CoV-2 infections and vaccines.SARS-CoV-2 感染与疫苗的免疫学
Semin Immunol. 2020 Aug;50:101422. doi: 10.1016/j.smim.2020.101422. Epub 2020 Nov 17.
4
Vaccines for SARS coronavirus 2 and the new normal in vaccinology.严重急性呼吸综合征冠状病毒2疫苗与疫苗学的新常态
Rev Med Virol. 2021 Mar;31(2):e2229. doi: 10.1002/rmv.2229. Epub 2021 Mar 5.
5
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.在初始候选疫苗获得紧急使用授权或批准上市后评估严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗
JAMA. 2021 Jan 19;325(3):221-222. doi: 10.1001/jama.2020.25127.
6
The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.mRNA疫苗的世纪:新冠疫苗与过敏
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):89-91. doi: 10.18176/jiaci.0665. Epub 2020 Jan 4.
7
The lightning-fast quest for COVID vaccines - and what it means for other diseases.对新冠疫苗的闪电式探索及其对其他疾病的意义。
Nature. 2021 Jan;589(7840):16-18. doi: 10.1038/d41586-020-03626-1.
8
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.COVID-19 疫苗的免疫学替代终点:我们现有的证据与我们所需的证据。
Signal Transduct Target Ther. 2021 Feb 2;6(1):48. doi: 10.1038/s41392-021-00481-y.
9
Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.了解新型冠状病毒肺炎的动态;对治疗干预、疫苗研发和行动管制的影响。
Br J Biomed Sci. 2020 Oct;77(4):168-184. doi: 10.1080/09674845.2020.1826136.
10
Vaccines for neglected, emerging and re-emerging diseases.被忽视、新发和再发传染病的疫苗。
Semin Immunol. 2020 Aug;50:101423. doi: 10.1016/j.smim.2020.101423. Epub 2020 Nov 26.

引用本文的文献

1
Artificial intelligence in vaccine research and development: an umbrella review.疫苗研发中的人工智能:一项综合综述
Front Immunol. 2025 May 8;16:1567116. doi: 10.3389/fimmu.2025.1567116. eCollection 2025.
2
Accelerated vaccine process development by orthogonal protein characterization.通过正交蛋白质表征加速疫苗工艺开发
Sci Rep. 2025 Apr 7;15(1):11831. doi: 10.1038/s41598-025-96642-y.
3
A novel vaccine strategy using quick and easy conversion of bacterial pathogens to unnatural amino acid-auxotrophic suicide derivatives.

本文引用的文献

1
COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.利用反向疫苗学和机器学习设计 COVID-19 冠状病毒疫苗。
Front Immunol. 2020 Jul 3;11:1581. doi: 10.3389/fimmu.2020.01581. eCollection 2020.
2
Development of an inactivated vaccine candidate for SARS-CoV-2.SARS-CoV-2 灭活疫苗候选物的研发。
Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.
3
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.
一种新型疫苗策略,利用快速简便地将细菌病原体转化为非天然氨基酸营养缺陷型自杀衍生物。
Microbiol Spectr. 2024 Apr 2;12(4):e0355723. doi: 10.1128/spectrum.03557-23. Epub 2024 Feb 22.
4
The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.追求更有效的疫苗市场 - 机遇、挑战以及 SARS-CoV-2 大流行带来的变化。
Vaccine. 2024 Apr 8;42 Suppl 1(Suppl 1):S64-S72. doi: 10.1016/j.vaccine.2022.07.032. Epub 2022 Oct 21.
5
Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease.PHV02 活、减毒重组水疱性口炎病毒载体疫苗对尼帕病毒病提供的免疫相关性。
Front Immunol. 2023 Sep 4;14:1216225. doi: 10.3389/fimmu.2023.1216225. eCollection 2023.
6
CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness.用于疫苗开发以加速进程和增强大流行防范能力的CMC策略与先进技术
Vaccines (Basel). 2023 Jun 26;11(7):1153. doi: 10.3390/vaccines11071153.
7
Reverse Vaccinology for Influenza A Virus: From Genome Sequencing to Vaccine Design.甲型流感病毒反向疫苗学:从基因组测序到疫苗设计。
Methods Mol Biol. 2023;2673:401-410. doi: 10.1007/978-1-0716-3239-0_27.
8
Immunoinformatics Approaches for Vaccine Design: A Fast and Secure Strategy for Successful Vaccine Development.疫苗设计的免疫信息学方法:成功开发疫苗的快速且可靠策略。
Vaccines (Basel). 2023 Jan 19;11(2):221. doi: 10.3390/vaccines11020221.
9
Implications for COVID-19 vaccine uptake: A systematic review.对 COVID-19 疫苗接种的影响:系统评价。
J Infect Public Health. 2023 Mar;16(3):441-466. doi: 10.1016/j.jiph.2023.01.020. Epub 2023 Jan 30.
10
A gaps-and-needs analysis of vaccine R&D in Europe: Recommendations to improve the research infrastructure.欧洲疫苗研发的差距和需求分析:改善研究基础设施的建议。
Biologicals. 2022 Apr;76:15-23. doi: 10.1016/j.biologicals.2022.02.003. Epub 2022 Feb 26.
人源单克隆抗体可阻断严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白与血管紧张素转换酶2受体的结合。
Cell Mol Immunol. 2020 Jun;17(6):647-649. doi: 10.1038/s41423-020-0426-7. Epub 2020 Apr 20.
4
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.人类挑战研究加速冠状病毒疫苗许可。
J Infect Dis. 2020 May 11;221(11):1752-1756. doi: 10.1093/infdis/jiaa152.
5
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.2019 年新型冠状病毒刺突蛋白在预融合构象的冷冻电镜结构
Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.
6
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England.英格兰婴儿接种脑膜炎 B 型疫苗(4CMenB)。
N Engl J Med. 2020 Jan 23;382(4):309-317. doi: 10.1056/NEJMoa1901229.
7
FDA Approval and Regulation of Pharmaceuticals, 1983-2018.FDA 对药品的批准与监管,1983-2018 年。
JAMA. 2020 Jan 14;323(2):164-176. doi: 10.1001/jama.2019.20288.
8
Reform at the FDA-In Need of Reform.美国食品药品监督管理局的改革——自身也需要改革
JAMA. 2020 Jan 14;323(2):123-124. doi: 10.1001/jama.2019.20538.
9
Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium.鉴定法定抗病毒疫苗反应原性的潜在生物标志物:由 BIOVACSAFE 联盟开展的随机对照临床试验。
Sci Rep. 2019 Dec 30;9(1):20362. doi: 10.1038/s41598-019-56994-8.
10
Human monoclonal antibodies for discovery, therapy, and vaccine acceleration.用于发现、治疗和疫苗加速的人源单克隆抗体。
Curr Opin Immunol. 2019 Aug;59:130-134. doi: 10.1016/j.coi.2019.07.005. Epub 2019 Aug 23.